1. Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity

   • Luis M. Ruilope
   • Antonio Coca
   • Manuel Luque

   Invited Commentary Pages: 261 - 264

2. Web alert

   News Pages: 265 - 266

3. Literature alert

   Abstract Pages: 267 - 271

4. Putting LIFE into hypertension

   • Michael A. Weber

   Clinical Trials Report Pages: 275 - 277

5. Is fixed combination therapy appropriate for initial hypertension treatment?

   • William J. Elliott

   OriginalPaper Pages: 278 - 285

6. Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in African-Americans?

   • Andrew Fenves
   • C. Venkata S. Ram

   OriginalPaper Pages: 286 - 289

7. Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?

   • Sumeska Thavarajah
   • George A. Mansoor

   OriginalPaper Pages: 290 - 297

8. Fixed low-dose combination therapy for hypertension

   • Bernard Waeber

   OriginalPaper Pages: 298 - 306

9. Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? pro position

   • Jay N. Cohn

   OriginalPaper Pages: 307 - 310

10. Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? con position

    • Keith C. Ferdinand
    • Claudia C. Serrano
    • Daphne P. Ferdinand

    OriginalPaper Pages: 311 - 318

11. Angiotensin-receptor blockers: Another victory

    • Domenic A. Sica

    Clinical Trials Report Pages: 321 - 323

12. Renal protection by antihypertensive therapy

    • Luis M. Ruilope
    • Julian Segura

    OriginalPaper Pages: 324 - 328

13. Low sodium diet after DASH: Has the situation changed?

    • Hillel W. Cohen
    • Michael H. Alderman

    OriginalPaper Pages: 329 - 332